In a recent Nature Communications article, Dr. Bill Chen‘s lab discuss how a high-throughput screen could be used to identify FDA-approved compounds that may resist SARS-CoV-2 infection.

“I grew up in China and came to the U.S. in 2003, the year of the first SARS outbreak… The moment one of my junior faculty members said, ‘This is going to hit the U.S.,’ I said, ‘I agree with you because I experienced the last one.’ That’s why we quickly shifted our work to SARS-CoV-2…”

– Dr. Bill Chen